About the TLC conference

The 2nd Annual Texas Lung Cancer Conference brings some of the leading lung cancer experts in the nation together with community oncologists to discuss the latest updates and explain some of the emerging controversies in the diagnosis and management of lung cancer and review some of the key emerging controversies in the field.

This two-day CE event is designed to provide attendees with the knowledge needed to confidently navigate the increasingly complex field of lung cancer and its treatment landscape. Attendees will learn the current standards of care for targeted therapy and immunotherapy from the investigators driving the field. Focused, engaging lectures will cover diagnostics, from the basics, explaining next-generation sequencing and liquid biopsies, to the cutting edge, speculating on dynamic monitoring and the latest in biomarkers.

Sessions on targeted therapy will demonstrate how our standards of care were established and help clinicians navigate issues with resistance and toxicity. Immunotherapy sessions will provide a framework for treatment selection and highlight the latest efforts to overcome and prevent resistance. There will be sessions dedicated to the treatment of advanced lung cancer as well as earlier stage lung cancer, discussing the most recent data for neoadjuvant and adjuvant therapy. Other sessions will be dedicated to less common tumors like small cell lung cancer and mesothelioma as well as emerging drug classes such as antibody-drug conjugates. With an eye to the future, special lectures on artificial intelligence, health policy, drug access and social media will keep attendees on the cutting edge . Case studies and extended Q&A sessions will follow the evidence-based presentations for each topic in order to facilitate discussion on applicability of results and guidelines in the clinical setting for the practicing providers. This will provide an opportunity for more interaction and greater engagement, focused on the practical application of the data and best practices in treating patients today.

There are now many different options available to patients with lung cancer; our faculty will thoughtfully debate some of the different treatment strategies currently in use. Throughout the conference, there will be ample time for live audience questions and opportunities for networking and personal discussions. The Texas Lung Cancer Conference is meant to provide attendees with the practical tools needed to provide the most current, evidence-based care for patients with lung cancer.